John Hood and his team sold Impact Biomedicines, Inc. – the company he co-founded in 2017 to develop the JAK2 inhibitor Inrebic (fedratinib) for myelofibrosis – to Celgene Corporation for $1.1bn up front in early 2018 and then the former Impact CEO took a few weeks off before seeking out his next project. Now, more than two years later, Hood has officially launched his latest start-up, known as Endeavor BioMedicines.
Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
Co-Founded By Former Impact Biomedicines CEO, Initial Focus Is IPF
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
More from Financing
More from Business
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.